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Aims Raised blood pressure (BP) is the biggest contributor to mortality and disease burden worldwide and fewer than
half of those with hypertension are aware of it. May Measurement Month (MMM) is a global campaign set up in
2017, to raise awareness of high BP and as a pragmatic solution to a lack of formal screening worldwide. The 2018
campaign was expanded, aiming to include more participants and countries.
...................................................................................................................................................................................................
Methods
and results
Eighty-nine countries participated in MMM 2018. Volunteers (>_18 years) were recruited through opportunistic
sampling at a variety of screening sites. Each participant had three BP measurements and completed a questionnaire
on demographic, lifestyle, and environmental factors. Hypertension was defined as a systolic BP >_140 mmHg or dia-
stolic BP >_90 mmHg, or taking antihypertensive medication. In total, 74.9% of screenees provided three BP read-
ings. Multiple imputation using chained equations was used to impute missing readings. 1 504 963 individuals (mean
age 45.3 years; 52.4% female) were screened. After multiple imputation, 502 079 (33.4%) individuals had hyperten-
sion, of whom 59.5% were aware of their diagnosis and 55.3% were taking antihypertensive medication. Of those
on medication, 60.0% were controlled and of all hypertensives, 33.2% were controlled. We detected 224 285 indi-
viduals with untreated hypertension and 111 214 individuals with inadequately treated (systolic BP >_ 140 mmHg or
diastolic BP >_ 90 mmHg) hypertension.
...................................................................................................................................................................................................
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Conclusion May Measurement Month expanded significantly compared with 2017, including more participants in more countries.
The campaign identified over 335 000 adults with untreated or inadequately treated hypertension. In the absence of
systematic screening programmes, MMM was effective at raising awareness at least among these individuals at risk.
                                                                                                                                                                                                                   
Keywords Hypertension • Blood pressure • Screening • Global • Treatment • Control
Introduction
Raised blood pressure (BP) continues to be the biggest contributor
to the global burden of disease and mortality, with 10.4 million
hypertension-related deaths in 2017.1 Hypertension affects over 1
billion adults worldwide and is forecast to affect over 1.5 billion by
2025.2 Despite the availability of effective treatments, only a small mi-
nority of those affected have their BPs controlled even to what are
currently considered conservative targets (<140 mmHg systolic and
<90 mmHg diastolic BP).3–5 This shortfall is largely due to the fact
that only a minority of the hypertensive population receive BP-
lowering treatment, which in turn reflects that the majority have not
had their BP measured. As recognized by the World Heart
Federation6 and the Lancet Commission on Hypertension,7 a critical
route to maximize improvements in BP control among hypertensive
adults is to enhance awareness of the condition.
Hence, in 2016 the International Society of Hypertension (ISH)
announced its intention to initiate and lead a global campaign
designed to raise awareness of the importance of BP and to act as a
pragmatic temporary solution to the shortfall in BP screening pro-
grammes. This campaign, May Measurement Month (MMM) 2017,
was designed to expand on and standardize the activities of the an-
nual World Hypertension Day (17 May) which had been an inter-
national event since 2005.8 The initial MMM survey took place in
2017 in 80 countries, screening over 1.2 million adults.9 The positive
feedback from global investigators and the finding of over 250 000
adults with either untreated or inadequately treated hypertension
provided sufficient stimulus to repeat the campaign on an annual basis
with the ultimate aim of using these MMM data to motivate govern-
ments and health policy-makers to improve BP screening facilities
and BP measurement in those parts of the world where such facilities
are particularly poor. Specific aims for MMM 2018 were to grow the
campaign for greater international outreach and impact by including
more participants in more countries and to enhance the quality of
the data collected compared with MMM 2017.
Methods
Study design
The MMM survey is a cross-sectional opportunistic study of BPs of volun-
teer adults aged 18 years or more. Over 100 countries were contacted
either via those who had collaborated in MMM 2017 or via other national
and international hypertension, cardiovascular or renal societies. In each
country, one or more national leaders were identified to take the respon-
sibility of acquiring national ethical clearance for the survey (if required)
and to identify volunteer staff to set up screening sites and measure BPs.
The protocol produced for MMM 2017 (www.maymeasure.com) was
modified slightly on the feedback and input from the 2017 investigators
and distributed to all national leaders potentially collaborating in 2018.
The website that was produced for MMM in 2017 was updated and
included training materials on BP measurement, and campaign promo-
tional materials.
Staff identified in each country set up screening sites in a wide range of
locations including hospitals, primary care clinics, indoor and outdoor
public places, places of worship, pharmacies, and workplaces. The cam-
paign was promoted internationally by the ISH and the World
Hypertension League and locally through television, radio, the media, and
social media. Endorsements from sporting, political, and national celebri-
ties were also used.
Volunteers were recruited at local sites using convenience sampling.
Having been made aware of the availability of BP screening, those adults
who wished to take advantage of the campaign attended one of the avail-
able MMM screening sites and were therefore self-referred. The cam-
paign was targeted ideally at those who had not had their BP measured in
the previous year, but participants who presented and had been screened
more recently were not excluded from the study.
Volunteer staff were trained to measure BP using either automated or
manual sphygmomanometers via video recordings housed on the MMM
website and via face-to-face on-site training. Standard methods for BP
measurement were recommended to include three sitting recordings
taken at 1 min intervals, from either the right or left arm, with pulse rate
measurements between BP recordings. In 2017 and 2018, 14 000
Omron BP devices (Omron Healthcare, Kyoto, Japan) were distributed
to MMM sites where insufficient devices were available. In total, 87.3% of
readings were taken using Omron devices. Otherwise, locally available
devices were used to measure BP with a recommendation to use auto-
mated devices where possible.
Prior to BP measurement, a questionnaire was used to collect limited
data from each participant. The questionnaire was slightly modified from
MMM 2017 to improve clarity and data quality (see Supplementary ma-
terial online, Appendix). Height and weight were recorded where facilities
were available or estimated by screenees if not.
Hypertension was defined as a systolic BP of >_140 mmHg or a diastolic
BP of >_90 mmHg, on the basis of the mean of the second and third BP
recording. Those taking antihypertensive medications were also assumed
to have hypertension and to be aware of their condition. Among those
on treatment, controlled BP was defined as a systolic BP of <140 mmHg
and a diastolic BP < 90 mmHg. Screenees found to have untreated or in-
adequately treated hypertension were provided with evidence-based
dietary and lifestyle advice as to how to lower BP (Ten Top Tips: see
Supplementary material online, Appendix). Advice for further follow-up of
their raised BP was also provided, tailored by national investigators based
on locally available facilities.
Data handling and statistical analysis
Data were entered via a bespoke MMM mobile application, available in
eight languages (Arabic, Chinese, English, French, Hindi, Polish,
Portuguese, and Spanish). Where, for logistic reasons or investigator
preference, the mobile application was not used, data were entered on
pre-prepared paper forms and transferred later to spreadsheets or the
mobile application.
Data were cleaned locally and/or centrally depending on local capacity,
following rules with cut-off ranges devised and provided to all sites (see
Supplementary material online, Appendix). Countries submitting fewer
MMM: A pragmatic global screening campaign to raise awareness of BP 2007
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than 10 screenees were excluded from analyses due to concerns over
the validity of these screening sites.
Data from 89 countries were submitted, collated centrally, and ana-
lysed using Stata version 14.2 (StataCorp 2015). Countries were grouped
into seven regions based on the UN geographical classification, with
minor modifications to match the regions used in 2017.10 Classification of
country economic income was derived from data from the World
Bank.11
Comparisons of the first, second, and third BP readings were made
among the 1 126 495 individuals with all three readings available. For all
further analyses, the mean of the second and third readings was used.
Where one or more BP measurements were missing, multiple imputation
by chained equations was used, assuming that missingness was dependent
on the observed data (Missing At Random).
Multiple imputation was conducted for those with complete data on
age, sex, ethnicity, and use of antihypertensive medication. The imput-
ation model incorporated all variables included in the further analyses,
required to avoid bias in the analyses.12 Each of the three systolic BP and
three diastolic BP readings were also included in the model, along with
the mean of the second and third readings, following the ‘just another
variable’ approach.13 Twenty-five imputations were created, chosen on
the basis of the percentage of missing data in the mean BP readings, and
confirmed by the Monte Carlo errors of the estimates (at <10% of the
standard errors).
In participants for whom the mean reading could not be imputed, due
to missing one or more of age, sex, ethnicity, or antihypertensive medica-
tion, a reduced imputation model using only the individual BP readings was
used. The primary analysis combined the data imputed using the complex
and reduced model (n= 1 504 963). Sensitivity analyses were performed
using the complete cases, reduced model, complex model, combination
(primary) model, and also comparing the MMM 2017 imputation model. A
full description of the imputation method, along with sensitivity analyses
can be found in the Supplementary material online, Appendix.
For comparisons of BP across regions, age and sex standardization was
carried out, based on the World Health Organization world age-standard
population, and assuming an equal ratio of males to females.14 Measures
of association were analysed using the complex imputation model (i.e.
not including those with missing data in age, sex, ethnicity, or antihyper-
tensive medication). Linear mixed models were run separately for systolic
and diastolic BP with a random intercept model to account for country-
level clustering. All models were adjusted for age, sex, and use of
antihypertensive medication, with age incorporated as a restricted cubic
spline with five knots, and inclusion of an interaction between age and
sex. The association between BP and heart rate was analysed using linear
mixed effects models which compared the BP with heart rate at each
reading, and accounted for repeated measurement within each partici-
pant using a random intercept.
Results
Participant characteristics
Data on 1 504 963 participants from 89 countries (see
Supplementary material online, Appendix Table A2) were cleaned, col-
lated, and analysed. Of these data, 12.4% were submitted via the
bespoke mobile application. Rates of complete data collection for in-
dividual variables were improved compared with 2017, with only
0.9% missing data on sex, and only 2.1% missing data on age (for full
details see Supplementary material online, Appendix Table A3). One-
third of participants were screened in a hospital or medical clinic, and
105 009 (7.0%) screenees had been screened in MMM 2017.
Participants were stratified across seven regions with significant dif-
ferences in mean ages and sex distribution across regions (Table 1).
South Asia contributed the largest proportion of screenees (26%)
and Europe the least (5.4%). More women than men were screened
in all regions except South Asia and the North Africa and Middle
East. Mean ages were lowest in the North African and Middle East re-
gion for both women (34.9 years) and men (36.6 years) and highest in
the Americas for both women (49.5 years) and men (51.3 years). Use
of antihypertensive medication also varied from 9.0% in sub-Saharan
Africa, to 32.7% in the Americas. The differential distributions of age,
sex, and medication use across the seven regions highlight the need
for adjustment of these three variables when making comparisons
among regions.
The percentages of participants from high-income, upper-middle,
lower-middle, and low-income countries were 12.3%, 30.0%, 54.4%,
and 3.4% respectively. Of 1 504 963 screenees, 111 374 (8.5%)
reported having diabetes, 61 174 (4.6%) reported a history of myo-
cardial infarction (MI), 42 010 (3.2%) reported a history of stroke,
........................................... ...........................................
....................................................................................................................................................................................................................
Table 1 Total participants worldwide and by region with distributions of age, sex, and antihypertensive medication
use
Region Total participants Female Male On antihypertensive
medication
Total Mean age
(years)
Total Mean age
(years)
South Asia 391 079 (26.0%) 160 797 (41.2%) 42.0 229 313 (58.8%) 42.9 75 225 (19.6%)
East Asia 304 423 (20.2%) 162 526 (53.4%) 48.1 141 818 (46.6%) 49.3 55 230 (18.5%)
South-east Asia and Australasia 293 948 (19.5%) 186 387 (65.0%) 46.6 100 339 (35.0%) 47.0 52 173 (19.8%)
Americas 189 560 (12.6%) 111 408 (59.4%) 49.5 76 014 (40.6%) 51.3 54 031 (32.7%)
Sub-Saharan Africa 151 924 (10.1%) 80 117 (52.8%) 40.0 71 609 (47.2%) 39.9 12 462 (9.0%)
Northern Africa and Middle East 93 465 (6.2%) 38 448 (42.4%) 34.9 52 303 (57.6%) 36.6 7895 (10.1%)
Europe 80 564 (5.4%) 48 304 (60.4%) 49.3 31 619 (39.6%) 50.0 20 778 (28.6%)
Worldwide 1 504 963 787 987 (52.8%) 45.3 703 015 (47.2%) 45.3 277 794 (19.8%)
Note: 982 individuals with gender defined as ‘other’ and 12 979 individuals with gender not recorded are not included in the distribution of sex.
2008 T. Beaney et al.
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..167 487 (12.3%) reported current smoking, 59 210 (4.6%) reported
alcohol consumption >_once per week, and 13 233 (1.7%) of women
reported being pregnant. Both height and weight were recorded in
91.4% of participants, but at least one of height and weight was esti-
mated rather than measured in 24.2% of screenees. The mean body
mass indexes (BMIs) of men and women were 24.6 kg/m2 (SD 4.5)
and 24.3 kg/m2 (SD 4.9), respectively (see Supplementary material
online, Appendix Table A3).
Variation across blood pressure readings
Of all participants, 1 126 495 (74.9%) had all 3 BP readings recorded
(see Supplementary material online, Appendix Table A1). Blood pres-
sures decreased on average by 3.0/2.0 mmHg between the first and
third readings (Table 2). Similarly, the proportion of screenees with
hypertension decreased on subsequent readings with a 4.0% differ-
ence in hypertension prevalence based on the first and third reading.
The lowest prevalence of hypertension was found using the mean of
the second and third readings (Table 2).
For participants missing the second and/or third BP reading, mul-
tiple imputation was used to impute the mean of the two readings.
Using the complex model (for those with age, sex, ethnicity, and anti-
hypertensive use all documented), imputations were carried out for a
total of 237 871 participants. For the remaining 137 556 participants,
the simple imputation model was used. A total of 25 imputations
were created.
Numbers with hypertension
After imputation, the mean BP worldwide was 123.1/77.9 mmHg
(95% confidence interval 123.0/77.9–123.1/77.9). Mean unadjusted
BPs ranged from 119.3/76.4 mmHg in East Asia to 127.3/79.3 mmHg
in Europe (Table 3). After age and sex standardization according to
the WHO population, East Asia still had the lowest mean BPs (117.0/
75.4 mmHg), whilst South Asia and Europe had the highest levels
(124.6/78.1 mmHg and 124.6/78.4 mmHg, respectively). Worldwide,
the mean BP of all those not taking antihypertensive medication was
120.0/76.7 mmHg and of those taking antihypertensive medication
was 127.7/80.0 mmHg.
Following imputation, 502 079 (33.4%) participants were found to
have hypertension (95% confidence interval 33.3%–33.4%) (Table 4).
Of these, 298 940 (59.5%) were aware of their condition and 277
794 (55.3%) were on treatment. Of those on treatment, 166 580
(60.0%) were controlled and hence 33.2% of all those with hyperten-
sion were controlled. Of 335 499 screenees found to have a systolic
BP >_140 mmHg or diastolic BP >_90 mmHg, 224 285 (66.9%) were
not on antihypertensive treatment and 111 214 (33.1%) were on
antihypertensive treatment. Of all participants screened worldwide
....................................................................................................................................................................................................................
Table 2 Mean blood pressure, number and percentage with hypertension across readings of those with all three
readings (n51 126 495)
BP reading Systolic
(mmHg)
Diastolic
(mmHg)
Number with
hypertension
Proportion with
hypertension (%)
1 124.8 79.1 433 011 38.4
2 122.9 77.9 401 364 35.6
3 121.8 77.1 387 440 34.4
Mean of 1 and 2 124.0 78.7 397 593 35.3
Mean of 2 and 3 122.5 77.7 377 263 33.5
Mean of 1 and 2 and 3 123.2 78.0 378 835 33.6
....................................................................
................................................... ....................................................................
....................................................................................................................................................................................................................
Table 3 Mean blood pressures after imputation, before and after standardization for age and sex
Standardized for age and sex
Region Mean BP (mmHg) Mean BP (mmHg)
Systolic Diastolic Systolic Diastolic
South Asia 125.1 78.4 124.6 78.1
East Asia 119.3 76.4 117.0 75.4
South-East Asia and Australasia 122.6 78.6 121.1 78.1
Americas 124.3 77.1 122.1 76.7
Sub-Saharan Africa 123.3 78.1 124.2 78.3
Northern Africa and Middle East 121.8 78.5 122.8 78.4
Europe 127.3 79.3 124.6 78.4
Worldwide 123.1 77.9 122.0 77.5
MMM: A pragmatic global screening campaign to raise awareness of BP 2009
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who were not on antihypertensive medication, 18.3% were found to
have hypertension. Following standardization for age and sex, 17.9%
of participants not on antihypertensive medication were found to
have hypertension, with the lowest proportion in East Asia (13.9%)
and the highest proportion in Northern Africa and the Middle East
(21.4%) (Supplementary material online, Appendix Table A6).
Sensitivity analyses showed only minor differences in the mean BPs
and in the proportions with hypertension. In the complete case ana-
lysis (before imputation), of 1 129 536 individuals with a mean of the
second and third readings available, 33.6% were found to have hyper-
tension (95% confidence interval 33.5%–33.7%). This compared with
33.4% using the 2017 imputation model, 33.4% using the reduced MI
model, 33.0% using the complex MI model and 33.4% using the com-
bined primary model. Full details of the results from the sensitivity
analyses along with estimates of precision and Monte Carlo errors
are shown in the Supplementary material online, Appendix Tables A4
and A5.
Differences in BP parameters and management were apparent
across regions, with the lowest proportion of all hypertensive partici-
pants on medication in Northern Africa and the Middle East (32.1%),
and the highest proportion in the Americas (70.6%). Of those on
medication, control rates were lowest in sub-Saharan Africa (45.1%)
and highest in South Asia (70.4%).
Of 105 009 (7.0%) of individuals who had also participated in
MMM 2017, the proportion with hypertension was 45.1%, compared
with 32.5% who did not participate in MMM 2017.
Of all participants, 43.3% had had a BP check within the last
12 months. Of those who had not had a BP check in the last year, the
mean BP was significantly lower than in those who had (122.1/
77.5 mmHg vs. 124.3/78.5 mmHg), with the proportion with hyperten-
sion lower in those not checked in the last 12 months (24.7% vs.
44.7%). Comparison across country income strata showed lower pro-
portions on treatment and lower control rates among the treated in
low-income countries relative to other income levels (see Figure 1).
Blood pressure associations
Based on linear mixed models, the global association between age
and systolic BP in men and women who were not receiving
antihypertensive treatment showed a linear increase, with the mean
BP in women exceeding the mean BP in men at 75 years of age. For
diastolic BP, the relationship shows an inverted U shape, with highest
levels at age 50–55 years, and with BP in women lower than in men
until aged 85–90 years (Figure 2).
After adjustment for age and sex (including an interaction between
age and sex) systolic and diastolic BPs were significantly higher in peo-
ple who were taking antihypertensive medications (Figure 3). Higher
BPs were also seen in those who reported having previously been
told they had high BP, independent of the association with medication
use. After adjusting for age, sex, and antihypertensive medication, sig-
nificantly lower systolic and diastolic BPs were seen in those with a
history of diabetes, stroke, and MI, compared to those without.
Systolic and diastolic BPs were lower when measured on the left
compared to the right arm, and in pregnant women compared to
women who were not pregnant (Figure 4). Higher BPs were seen in
alcohol drinkers, with a linear dose-dependent relationship, and
slightly higher BPs were seen in those who were fasting at the time of
....................................................................................................................................................................................................................
Table 4 Key proportions for participants with hypertension, worldwide, and by region, after imputation
Region Number with
hypertension
Proportion with
hypertension (%)
Proportion of
hypertensives
aware (%)
Proportion
of hypertensives
on medication (%)
Proportion of those
on medication with
controlled BP (%)
Proportion of
all hypertensives
controlled (%)
South Asia 132 173 33.8 59.5 56.9 70.4 40.0
East Asia 93 499 30.7 64.0 59.1 63.2 37.3
South-East Asia and
Australasia
104 148 35.4 50.8 50.1 48.7 24.4
Americas 76 574 40.4 76.7 70.6 60.9 43.0
Sub-Saharan Africa 37 603 24.8 43.6 33.1 45.1 15.0
Northern Africa and
Middle East
24 579 26.3 35.7 32.1 58.6 18.8
Europe 33 504 41.6 71.0 62.0 48.9 30.3
Worldwide 502 079 33.4 59.5 55.3 60.0 33.2
Figure 1 Proportions of hypertensives not on medication, on
medication and controlled, on medication and uncontrolled, by
country income strata.
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screening. Smokers showed no significant difference in BPs compared
with non-smokers.
A strong linear relationship was seen between both systolic and
diastolic BP and increasing levels of BMI (Figure 5), with a mean in-
crease of 6.7/4.1 mmHg comparing obese participants to those
considered underweight. A sensitivity analysis found no significant dif-
ference in this relationship using BMIs that were measured compared
with those that were estimated. A similarly strong linear relationship
was seen between diastolic BP and heart rate (Figure 6). The associ-
ation of systolic BP with heart rate was clear, but less pronounced.
Compared to hospital- or clinic-based measurements, BPs meas-
ured in pharmacies were significantly lower, while those taken in the
workplace were significantly higher (Supplementary material online,
Appendix Figure A1). Systolic BPs were highest on Saturday and lowest
Figure 2 Change in blood pressure with age and sex, excluding those on antihypertensive medication, from linear mixed model after imputation.
Note: shaded areas represent 95% confidence intervals.
Figure 3 Change in mean systolic and diastolic blood pressure compared to baseline group, for co-morbidities, adjusted for age, sex, and use of
antihypertensive medication, from linear mixed models. Note: Error bars represent 95% confidence intervals.
MMM: A pragmatic global screening campaign to raise awareness of BP 2011
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on Tuesday, with diastolic BP highest on a Monday. However, al-
though statistically significant, these effects were small being under
0.5 mmHg on average (Supplementary material online, Appendix
Figure A2). Additional adjustment for alcohol did not significantly af-
fect the association with day of week. There was no clear relationship
between BP levels and increasing levels of room temperature. Full
Figure 4 Change in mean systolic and diastolic blood pressure compared to baseline group, for other participant factors, adjusted for age, sex, and
use of anti-hypertensive medication (pregnancy adjusted for age and medication alone), from linear mixed models. Note: Error bars represent 95%
confidence intervals.
Figure 5 Change in mean systolic and diastolic blood pressure compared to baseline group, for body mass index category, adjusted for age, sex,
and use of antihypertensive medication, from linear mixed models. Note: Error bars represent 95% confidence intervals. Body Mass Index categories:
underweight: <18.5 kg/m2; healthy weight: 18.5–24.9 kg/m2; overweight: 25.0–29.9 kg/m2; obese: >_30.0 kg/m2.
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details of these analyses, along with coefficients and 95% confidence
intervals, are shown in the Supplementary material online, Appendix.
Discussion
May Measurement Month 2018 expanded on the unique achieve-
ments of MMM 2017 by including over 1.5 million screenees from
89 countries, replacing MMM 2017 as the largest synchronized, stand-
ardized, and multinational screening campaign of any cardiovascular
risk factor ever carried out. Equally importantly, the quality of data
collected was greatly improved compared with MMM 2017, with less
missing data, allowing a more rigorous and valid evaluation of the
associations between BP and those variables recorded.
Over a third of a million adults were identified as having untreated
(224 285) or inadequately treated (111 214) hypertension, reaffirm-
ing previously established low BP treatment and control rates3–5 and
the findings of MMM 2017.9 In addition, 59.5% of participants identi-
fied with hypertension were aware of having had a previous diagnosis
of hypertension. This was higher than the 46.5% awareness found in
the PURE study and may reflect our more contemporary data and/or
differential recruitment practices.3 However, with 40.5% of partici-
pants with hypertension unaware of having high BP, MMM can have a
substantial impact in raising awareness in this group.
Using the hitherto standard definition of hypertension
(>_140 mmHg systolic or >_90 mmHg diastolic or on treatment for
hypertension), the proportion of screenees with hypertension was
almost identical (33.4%) to that discovered in MMM 2017 (34.9%),
despite a different source of participants in terms of countries
included and the different relative distribution of numbers of
screenees among the countries. The proportion with hypertension
among the 105 009 participants screened in both MMM 2017 and
MMM 2018, was higher than in the rest of the population who were
not screened in 2017, suggesting that those found to have higher BPs
in 2017 were more likely to return for screening.
In our study, ‘hypertension’ was based on a single set of three readings,
contrary to optimal practice,15–17 but further measurements or ambula-
tory readings would not have been feasible due to both cost and logistics.
We might therefore expect spuriously high rates of hypertension through
inclusion of those with white coat hypertension. MMM 2018 data reaffirm
that the most conservative (and therefore likely the most accurate) diag-
nostic criteria for hypertension when based on three serial BP recordings
arose from the mean of the second and third BP readings, even though
the third reading was on average lower than the second. We recommend
that if treatment decisions have to be made on the basis of a single set of
readings—sadly all too common—this approach gives the optimal con-
servative information unless further readings can be taken.
Screenees were recruited by opportunistic, convenience sampling
and although sites generated a wide range of participants, comparison
of prevalence of hypertension across regions is inappropriate.
However, the associations of BP within the screened population are
internally valid18 and given the magnitude of the study and diversity of
participants, are likely to be externally valid. This is supported by the
strong reaffirmation of the well-established associations seen be-
tween higher BP and increasing age,19 BMI20 and levels of alcohol in-
take21 and lower BP with pregnancy.22
The largest disparities in BP levels among subgroups were those
observed across the range of BMIs (Figure 5), those who had previously
been told they had high BP and those taking antihypertensive medica-
tion. A similarly strong relationship was found with heart rate, but the
Figure 6 Change in mean systolic and diastolic blood pressure compared to baseline group, for heart rate category, adjusted for age, sex, and use
of anti-hypertensive medication, from linear mixed models. Note: Error bars represent 95% confidence intervals.
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effect was unexpectedly stronger with diastolic than with systolic BP.
We also found a surprising relationship of reduced BP in participants
with a history of diabetes, stroke, and MI after accounting for age, sex,
and medication use. The reasons for this are not clear, but could reflect
residual confounding, more aggressive BP treatment in these groups of
patients, post-MI heart failure, or unrecorded use of BP-lowering medi-
cation (e.g. if thought to be for a different indication).
In 2018, Ramadan started in May and for this reason, we added
a question on fasting status. Almost 100 000 MMM participants
were fasting and were found to have slightly higher BPs than those
who were not fasting—however, given the small difference
observed, this appears to be consistent with previous studies show-
ing no clinically significant effects of fasting in normotensive or
hypertensive patients.23,24 As found in MMM 2017, readings taken
on the right arm were higher than those measured on the left arm.
Compared with BPs measured in hospitals or clinics, BPs were
lower in all types of sites except the workplace. Whilst this might re-
flect a higher rate of hypertension among those screened in a medic-
al setting it may also reflect a version of the ‘white-coat’ effect.25
The relationship with ambient temperature was unclear and does
not fit with recent findings of reduced BP with higher room tempera-
tures.26 May Measurement Month results may have been confounded
by inappropriate documentation of outdoor temperatures rather
than indoor, or ignoring changes in room temperature throughout
the day. As in MMM 2017, systolic BPs were highest on Saturday and
lowest on Tuesday, but the size of the difference was small and the
relationship was unaffected by adjusting for alcohol.
Limitations
Limitations of MMM 2018 include that, although efforts to train those
measuring BPs were made, variations in the machines used and in the
environment during measurement mean that standardization of
measurement around the world was inevitably imperfect. While the
mobile application and data input templates were designed to minim-
ize errors during entry, inaccuracies did occur, requiring some meas-
urements to be dropped during the cleaning process. Despite this,
the strong corroboration in analyses based on estimated, compared
with measured, height and weight, suggest a high degree of validity.
The study protocol required three BP measurements for each partici-
pant, but at least one of these three measurements was not taken or
documented in a quarter of participants. The significant variation across
the first, second, and third readings had the potential to cause a large im-
pact in analysis and a possible over-diagnosis of hypertension. Our use of
multiple imputation allowed us to mitigate this effect and accurately esti-
mate the mean of the second and third reading from a single reading,
with results robust to a range of different imputation models.
In keeping with most hypertension surveys, the diagnosis of hyper-
tension was based on a single series of readings. This is not recom-
mended practice for diagnosis at the individual level16,17 but sadly is
all too commonly used in clinical practice.
A further limitation is that screenees were self-selected and oppor-
tunistic convenience sampling was used to include people who ideally,
had not had their BPs measured in the previous year. Hence the study
was, by design, not intended to give representative samples. A third of
measurements were taken in medical settings which might result in the
self-selection of a greater proportion of participants with hypertension.
However, as our results show, the absolute differences in mean BP
taken in different settings was small (under 2 mmHg systolic/diastolic).
Due to the potential self-selection bias introduced through the sam-
pling, underlying prevalence rates cannot be reported and compared,
and differences between countries and regions should be interpreted
in the context of the local characteristics of screening sites. Despite the
limitations, our results are in line with published data in smaller cohorts
demonstrating that 30–35% of adults have hypertension, with a high
proportion being unaware and a small percentage being treated to tar-
get.3–5 In addition, the results do provide ‘real-world’ data on the char-
acteristics of the participants who are likely to present to a volunteer-
based screening campaign, which for many countries may be a more
feasible option than a systematic screening programme.
The effect of diet and lifestyle advice given to all those with raised
BP (treated or not) could not be evaluated in the cross-sectional de-
sign, and hence the post-survey impact on awareness could not be
evaluated. However, plans to incorporate post-screening follow-up
are in progress for MMM 2019 and subsequent years. Furthermore,
at the individual level over 335 000 adults were made aware of their
raised BP levels and, given the extensive promotion of MMM via tele-
vision, radio, the media, and social media, we believe that awareness
at the population level was also increased. Although large improve-
ments in data quality were achieved in MMM 2018, only a minority
(12.4%) of the data were collected through the bespoke mobile appli-
cation. This resulted in slower data collection, cleaning, transfer, anal-
yses, and publication of results. Further improvements in data
collection are planned for MMM 2019.
Finally, for the logistic and financial reasons the survey was
restricted to use a relatively short questionnaire to collect data from
screenees. However, plans to extend and modify the questions each
year are in place. Efforts to include more screenees from low-income
countries will also be made in future years.
Future directions
May Measurement Month 2018 was achieved at a central cost of 14
cents per participant and 65 cents per identified case of untreated or
treated but uncontrolled hypertension, although most costs were
offset by having volunteer investigators, donated BP measurement
devices and locally raised funds. May Measurement Month 2018 con-
firms that mass screening of BP is feasible around the world at a rela-
tively low cost to raise awareness of BP in large numbers of people.
Although the ultimate aim of the MMM campaign is to use the data to
influence health policy on BP screening and management where it is
needed most, meanwhile, it provides stand-alone benefits likely to re-
duce the health burden due to raised BP.
Further analyses of all individual national datasets from MMM 2018
are in progress to update and expand on those based on MMM 2017
national data.27 It is hoped that this will help to facilitate dissemination
of local results and thereby potentially influence awareness and na-
tional policies related to the implications of BP screening and hyper-
tension management.
Conclusion
The results from MMM 2018 show that significant numbers of people
can be identified with untreated, or treated but uncontrolled,
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hypertension from an opportunistic, volunteer-driven screening cam-
paign. The growth from over 1.2 million screenees in 2017 to over 1.5
million in 2018 attests to the perceived efficacy amongst national inves-
tigators and volunteers in the ability of MMM to raise awareness of this
major and growing global health burden, at least in the significant num-
bers found to have raised BP. Given the urgency to act, as long as large
numbers of people with untreated or inadequately treated hyperten-
sion are identified, sufficient central support can be obtained, and suit-
able surveillance systems are still not available for many countries of
the world, we believe MMM should continue on an annual basis.
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Right-to-left shunt in cryptogenic cerebrovascular event: fleas and lice
Roberto Galea, KerstinWustmann, Bernhard Meier, and Lorenz R€aber*
Department of Cardiology, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland
* Corresponding author. Tel: 141 31 63 2 09 29, Email: lorenz.raeber@insel.ch
A 26-year-old woman with a history of transi-
ent ischaemic attack was referred for percuta-
neous closure of a patent foramen ovale (PFO)
diagnosed with transoesophageal echocardiog-
raphy (TOE). A TOE with bubble test and
Valsalva manoeuvre showed a PFO Grade II
(arrow) with an atrial septal aneurysm (Panel
A). The PFO was successfully closed with an
25mm Amplatzer PFO Occluder. The patient
was discharged on acetylsalicylic acid 100mg/
day and clopidogrel 75mg/day for 3months fol-
lowed by 3months of acetylsalicylic acid alone.
At 6months, a TOE showed the Amplatzer
PFO Occluder 25mm in correct position
(lower arrow). There was persistent right-left
shunt (RLS) from the region of the left pulmo-
nary veins (upper arrow) and not involving the
PFO (Panel B). A multislice computed tomogra-
phy (MSCT) was performed showing a pulmo-
nary arteriovenous fistula (PAVF) between the
inferior lingular artery and correlating pulmo-
nary vein (arrows) (Panels C and D). Cardiac
catheterization confirmed the MSCT findings
demonstrating a PAVF in the segment 5a left
(arrow, Panel E). The PAVF was successfully
closed with a 5-mm Amplatzer Vascular Plug II
(arrow, Panel F). The patient was discharged
without any antiplatelet therapy.
Three months later a TOE excluded RLS per-
sistence. The patient has remained symptom-
free since. This case emphasizes that different
RLS can coexist (fleas and lice) and contribute to
the development of cerebrovascular events.
The existence of PAVF should be always consid-
ered even in the presence of a PFO. Both can be corrected with a simple and innocuous catheter-based intervention.
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